Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for Relapsing Forms of Multiple Sclerosis at ECTRIMS 2021

 Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for Relapsing Forms of Multiple Sclerosis at ECTRIMS 2021

Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for Relapsing Forms of Multiple Sclerosis at ECTRIMS 2021

Shots:

  • The P-IIb LTS part A assesses tolebrutinib (5/15/30/60mg/day) in patients with RMS and in Part B, where all participants switched to the 60mg
  • The study demonstrated a reduction in MS disease activity as MRI and showed a favorable 1yrs. tolerability. “Mean EDSS scores across treatment groups ranged from 2.18 to 2.65 at baseline and remained relatively stable over 48 weeks. For the 60/60mg treatment group, mean (SD) score was 2.65 (1.22) at baseline and 2.45 (1.31) at Week 48; low MRI lesion activity in patients who started on or switched to 60mg. 98% of patients remained on treatment in P-IIb extension study @48wks.
  • @48wks. of the extension study, low Gd-enhancing lesions (<0.4) in the 60/60mg arm. Additionally, data from in vitro studies in human microglia extended previous observations that BTK-dependent inflammatory signaling can be modulated by tolebrutinib

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Medcity News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post